Dysbiosis-Driven Low-Grade Systemic Inflammation: Microbiome Protocol

A Mediterranean diet (MedDiet), characterised by high plant diversity, fermentable fibres, and polyphenol-rich foods, has been studied for its capacity to shift the gut microbiome toward anti-inflammatory configurations and modulate the bile acid–microbiome axis. Trial evidence associates MedDiet adherence with increased production of anti-inflammatory microbial metabolites relevant to systemic inflammatory load [id=73]. The dietary pattern is hypothesised to enrich butyrate-producing taxa and reduce pro-inflammatory enterotypes [id=88].

Partially hydrolysed guar gum (PHGG/OptiFibre) and psyllium have been studied as prebiotic substrates that selectively stimulate SCFA-producing bacteria, with measurable effects on gut microbiota metabolite profiles and carbohydrate metabolism. RCT data in metabolically dysregulated patients demonstrate shifts in SCFA production and improvements in microbial ecology markers [id=76, id=103]. SCFAs, particularly butyrate, are recognised mediators of intestinal barrier integrity and systemic immune tone [id=86].

Dietary exposure to antimicrobial residues and ultra-processed food components can perturb colonisation resistance and promote expansion of antimicrobial resistance gene (ARG)-carrying taxa in the gut. Evidence from food-safety microbiome research identifies diet as a modifiable vector of exogenous microbial and chemical disruption that compounds endogenous dysbiosis [id=85]. Reducing this exposure is framed as preserving the ecological niche of keystone commensal species [id=24].

Sleep disruption and circadian misalignment are recognised as upstream modulators of gut microbiota composition and intestinal barrier function, with downstream effects on systemic inflammatory markers. Longitudinal cohort evidence tracking microbiome dynamics over multiple timescales identifies circadian-linked rhythmicity in microbial community structure [id=102]. This step recognises sleep as a modifiable lifestyle factor within a multi-pillar dysbiosis-management framework [id=100].

Chronic psychosocial stress perturbs the gut–brain axis bidirectionally, with evidence that stress-related neuroendocrine signals alter microbial composition and intestinal permeability, compounding dysbiosis-driven inflammation. Animal model evidence using the NF-κB/NLRP3 inflammasome pathway demonstrates that gut-brain axis disruption amplifies inflammatory cascades [id=126]. Observational and longitudinal cohort data support monitoring stress as a confounding driver of microbiome instability [id=102].

Probiotic interventions using defined single or multi-strain preparations have been evaluated in populations with dysbiosis-associated conditions, including paediatric T1D, with meta-analytic evidence showing modulation of inflammatory markers alongside shifts in microbiota composition [id=25]. Infant studies further demonstrate that specific strains (e.g. Lactobacillus reuteri) combined with vitamin D3 can influence early gut colonisation dynamics [id=75]. Mechanistic work in defined communities confirms that individual taxa contribute non-redundantly to community-level metabolic outputs [id=24].

The bile acid–gut microbiome axis is a key mechanistic interface through which dysbiosis drives systemic metabolic and inflammatory consequences. Evidence links taxa such as Prevotellaceae NK3B31 to secondary bile acid (e.g. 7-ketolithocholic acid) production with downstream metabolic benefits, suggesting that supporting bile acid diversity through fibre and dietary intervention is mechanistically rational [id=101]. This axis is also directly targeted in MedDiet RCT methodology [id=73].

Antibiotic exposure is one of the most potent and rapid disruptors of gut microbiota ecology, reducing colonisation resistance and enabling expansion of pathobionts and ARG-bearing strains. Review evidence emphasises that repeated or unnecessary antibiotic courses create persistent dysbiosis patterns that underpin low-grade systemic inflammation [id=85]. This step frames antibiotic stewardship as an adjunct 'supplement-avoidance' strategy within the protocol.

Although no included article directly RCTs exercise as the isolated intervention on dysbiosis-driven inflammation, mechanistic and observational cohort data consistently identify physical activity as a modulator of microbiota diversity and systemic inflammatory markers in populations with metabolic and immune dysregulation [id=100, id=72]. Post-bariatric surgery data illustrate that physiological shifts—including exercise-associated metabolic changes—accompany microbiota remodelling with reduced inflammatory tone [id=72].

Establishing a baseline microbiota profile using 16S rRNA amplicon sequencing or deep metagenomic sequencing enables identification of dysbiosis patterns—including keystone taxa depletion (e.g. butyrate producers such as Faecalibacterium prausnitzii) and pathobiont expansion—that mechanistically underpin inflammatory phenotype. Deep metagenomic data in post-stroke T2DM cohorts demonstrate reproducible dysbiosis signatures correlating with inflammatory and cognitive outcomes [id=86]. Enterotype characterisation has additional value for predicting therapeutic response trajectories [id=88].

Monitoring inflammatory biomarkers (e.g. hsCRP, IL-6, TNF-α, lipopolysaccharide-binding protein as a proxy for gut barrier dysfunction) provides objective quantification of protocol impact on systemic inflammation. Mechanistic studies in acute pancreatitis and dysbiosis models demonstrate that microbiota-mediated immune shifts (including PF4+ macrophage regulation and NF-κB pathway modulation) are reflected in measurable systemic cytokine changes [id=87, id=126]. Serial measurement allows dose-response and responder stratification.

Faecal short-chain fatty acid concentrations (acetate, propionate, butyrate) serve as functional indicators of microbiota fermentative capacity and ecosystem health, beyond compositional taxonomy alone. RCT evidence in T2DM patients receiving prebiotic fibre demonstrates detectable SCFA shifts as mechanistic intermediates linking intervention to metabolic and inflammatory outcomes [id=76]. SCFA profiling complements 16S/metagenomic data by capturing community-level metabolic function [id=103].

Microbiota community structure is dynamic and can shift substantially over weeks to months in response to dietary, probiotic, and lifestyle interventions. Longitudinal cohort methodology with multiple sampling timepoints—as employed in the Westlake Frequent-sampling Cohort design—enables detection of remodelling trajectories, stability, and resilience rather than single-point snapshots [id=102]. Post-bariatric surgery data further illustrate that procedure-specific microbiota dynamics unfold over months and require serial assessment to characterise [id=72].

In individuals with recent antibiotic exposure or recurrent infections, assessment of the gut resistome (ARG abundance and diversity) may reveal a dysbiosis component driven by ARG-bearing pathobionts that resist standard microbiome-restoration efforts. Food-safety-oriented microbiome research highlights ARG dynamics as a clinically relevant layer of gut ecology data that informs intervention selection [id=85]. This monitoring step is context-dependent rather than universal.

Faecal microbiota transplantation (FMT) is an emerging intervention for severe or refractory dysbiosis, currently under pilot RCT investigation for conditions including anorexia nervosa, with primary endpoints including engraftment dynamics, safety, and feasibility [id=117]. Given preliminary-tier evidence and non-trivial risks (including transmission of pathogens and unintended microbial engraftment), FMT is contraindicated outside of approved research protocols or specialist clinical settings. Immunocompromised individuals and those with active intestinal inflammation require particular caution.

Whilst probiotic supplementation demonstrates a favourable safety profile in healthy and mildly dysregulated populations, meta-analytic evidence in paediatric T1D and pilot FMT work acknowledge that bacteraemia and immune-related adverse events remain a concern in immunocompromised hosts [id=25, id=117]. Individuals receiving immunosuppressive therapy, those with active intestinal mucosal compromise, or patients with central venous access should be evaluated individually before initiating live microbial preparations.

Rapid escalation of fermentable dietary fibre can provoke bloating, increased luminal gas production, and osmotic effects that exacerbate symptoms in individuals with active inflammatory bowel disease, intestinal strictures, or gastroparesis. Psyllium and PHGG RCT protocols employ gradual dose titration to minimise these effects and account for inter-individual fermentation kinetics [id=103, id=76]. Clinicians should assess baseline gastrointestinal status before initiating prebiotic fibre protocols.